Description: Pixium Vision SA, a bioelectronics and brain machine interface technology company, specialized in neuromodulation application. It develops PRIMA System, a bionic vision system for patients with severe vision loss due to retinal degeneration caused by the dry atrophic form of Age-related Macular Degeneration (AMD); and to treat bilndness, which replace the normal physiological function of the eye's photoreceptor cells by electrically stimulating the nerve cells of the inner retina, which then transmit the visual information to the brain via the optic nerve. The company has collaboration agreements with Stanford University in California, Institut de la Vision, Moorfields Eye Hospital, Institute of Ocular Microsurgery, University Hospital, and UPMC. Pixium Vision SA was founded in 2011 and is based in Paris, France.
Home Page: www.pixium-vision.com
74 rue du Faubourg Saint-Antoine
Paris,
75012
France
Phone:
33 1 76 21 47 68
Officers
| Name | Title |
|---|---|
| Dr. Bernard Gilly Ph.D. | Exec. Chairman |
| Mr. Lloyd Diamond | CEO & Director |
| Mr. Offer Nonhoff | Chief Financial Officer |
| Dr. Lisa C. Olmos De Koo M.D., MBA | Chief Medical Advisor |
Exchange: PA
Country: FR
Currency: Euro (€)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 13.5461 |
| Price-to-Sales TTM: | 3.5923 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 43 |